Comparison · NCT00467870-sae
TU 750 mg vs TU 1000 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TU 750 mg vs TU 1000 mg: serious adverse events. Trial comparisons, record NCT00467870-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00467870-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.14 | 0.104 | 0.186 | wilson | |
| Risk in group 2 | 0.147 | 0.108 | 0.196 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00712 | -0.068 | 0.053 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.952 | 0.626 | 1.45 | log | |
| Odds ratio, group 1 over group 2 | 0.944 | 0.579 | 1.54 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on TU 750 mg than on TU 1000 mg | 140 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TU 750 mg | 750 mg TU in 3 mL oily solution, IM at baseline and during the study in Part A, C, or C2 (includes participants from A-750 mg, C-750 mg, and C2-750 mg) | 38 | 272 | EG000 |
| Group 2 | TU 1000 mg | 1000 mg TU in 4 mL oily solution, IM at any time during the study in Part A or B (includes participants from A-1000 mg, B-750 mg, and B-1000 mg) | 37 | 252 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Throughout the study (up to 3 years)
Source ClinicalTrials.gov
Trial
- Title
- Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
- NCT number
- NCT00467870
- Phases
- PHASE3
- Conditions
- Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Interventions
- Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Results first posted
- 2017-03-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00467870?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00467870-sae